Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q4 2021
Net profit, assets, equity and cash flow for Q4 2021, against the same period a year earlier, from the published financial statements.
Net profit148 millionEGP
Total assets577 millionEGP
Shareholders' equity358 millionEGP
Operating cash flow50.26 millionEGP
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q4 2021 was about 148 million EGP.
- Total assets at the end of Q4 2021 were about 577 million EGP, and shareholders' equity about 358 million EGP.
- Operating cash flow for Q4 2021 was positive at 50.26 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit148 million——
Gross profit480 million——
Total assets577 million——
Total liabilities219 million——
Shareholders' equity358 million——
Total liabilities and equity577 million——
Operating cash flow50.26 million——
Investing cash flow-5.82 million——
Financing cash flow-44.15 million——
Net change in cash291 thousand——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy